If you have been reading about peptide backbone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-09-12. Numbers and descriptions here follow the published literature rather than marketing material.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecule class | Synthetic peptide | Engineered triple receptor agonist |
| Molecular weight | Approximately 4731 Da | Reported value; depends on form |
| Receptor targets | GLP-1, GIP, glucagon | Simultaneous activation |
| Development code | LY3437943 | Internal company designation |
| Current status | Investigational | No approved indication reported |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Miso soup can be prepared in several ways, depending on the chef and the style of soup. Japanese recipes usually call for most vegetables to be cooked in the simmering dashi, particularly mushrooms, daikon, carrots, potatoes, tofu, and fish. There is a common myth that when miso paste is heated, the microorganisms are killed and the health benefits are reduced, but this is incorrect. In fact, the health benefits are due to nutrients produced by enzymes produced during the miso making process, not the bacteria in the miso. Miso soup and white rice are the central dishes of the traditional Japanese breakfast. The soup has been a favorite of commoners and royalty alike for many centuries, but there are also many other dishes involving breakfast. They are all quite small, some include egg, fish, and nattō which is a fermented soybean. The soup is usually served in lacquer bowls with lids and drunk directly from the bowl, though the solid ingredients are eaten with chopsticks. The bowl sometimes has a lid to keep heat and aroma in as well as to improve the presentation.
A Taylor cone refers to the cone observed in electrospinning, electrospraying and hydrodynamic spray processes from which a jet of charged particles emanates above a threshold voltage. Aside from electrospray ionization in mass spectrometry, the Taylor cone is important in field-emission electric propulsion (FEEP) and colloid thrusters used in fine control and high efficiency (low power) thrust of spacecraft.
=== Edward Burgess === Edward Burgess (David Wilmot) is the crusading editor-in-chief of FinDigest, the financial publication Jim Dycker writes for. Burgess tells Jim that his investigation into Tender's payment laundering does not have enough verifiable evidence, forcing him to run a heavily edited-down version of the piece. Burgess is later forced to fire Jim after an article reveals his collusion with short sellers at SternTao, as well as a sexual assault allegation from Tender assistant Hayley Clay, who Jim had followed to a club and spent the night with. After Jim dies of a drug overdose, Burgess is contacted by Sweetpea Golightly, who tells him that Jim was "more right than he realized" about Tender being fraudulent, and sets up a whistleblower deal for Tony Day, Tender's EMEA CFO who is the face of the company's suspicious acquisitions in the region. However, Burgess and Sweetpea's interview with Day is sabotaged by Whitney, who persuades Day mere minutes before to remain loyal to Tender. Harper later goes to Burgess and has him publish a claim (concocted by Yasmin) that the Labour government suppressed internal concerns about Tender. Burgess reluctantly agrees, and his article is subsequently amplified by Norton's tabloids, opening Tender to a new audit and a fraud investigation.
=== Compounds === Vacuoles in the tuber of S. affinis are rich in stachyose. Stachyose is a tetrasaccharide, consisting of galactose, glucose and fructose. Stachyose is evaluated to be about 230 mg/kg in dry tubers.
Promote their own products as healthy and unique, by clearly distinguishing their health claims from similar products, and by specifying naturally healthy ingredients. Consider extensions of existing brand lines. For example, Nestle extended their Boost product line by adding Kids Essentials to the line, thereby extending the adult-focused Boost line to a new market (children). Larger companies compete for market share by acquiring smaller companies that may own a particular market sector. For example, Coca-Cola purchased Glaceau from Energy Brands, and Odwalla, and Fuze Beverage from their respective founders, in order to increase Coca-Cola's market share. Explore new functional brands by identifying new markets and demands. Market segments of the functional beverage industry are divided mainly into four parts. Those include hydration, energy and rejuvenation, health and wellness, and weight management. Each segment has its own target market and consumers. Overlapping of target consumers does occur—not because of undefined market needs, but due to consumer acceptance of functional beverages.
Sources: en.wikipedia.org
== Pre-Proto-Hassuna == More recently, the concept of a very early 'Pre-Proto-Hassuna' pottery tradition has been introduced by some scholars. This has been prompted by more recent discoveries of still earlier pottery traditions. Pre-Proto-Hassuna refers to the Late Neolithic period in Upper Mesopotamia when the ceramic containers were just being introduced. The pottery vessels were still very few in number in these early settlements. At that time, the main emphasis was on the pottery with a mineral temper, as opposed to the plant-tempered pottery which came to predominate later. The time frame for this period was about 7000-6700 BC, and at this time stone vessels and White Ware were still being used in addition to pottery. Because of the narrow local emphasis in many pottery studies as of now, these earliest pottery traditions may be known in literature as:
==== Carbon-sulfur ==== Prenylcysteine lyase (PCLase) catalyzes the cleavage of prenylcysteine (a protein modification) to form an isoprenoid aldehyde and the freed cysteine residue on the protein target. The FAD is non-covalently bound to PCLase. Not many mechanistic studies have been done looking at the reactions of the flavin, but the proposed mechanism is shown below. A hydride transfer from the C1 of the prenyl moiety to FAD is proposed, resulting in the reduction of the flavin to FADH2. COformED IS a carbocation that is stabilized by the neighboring sulfur atom. FADH2 then reacts with molecular oxygen to restore the oxidized enzyme.
Many RNAs are involved in modifying other RNAs. Introns are spliced out of pre-mRNA by spliceosomes, which contain several small nuclear RNAs (snRNA), or the introns can be ribozymes that are spliced by themselves. RNA can also be altered by having its nucleotides modified to nucleotides other than A, C, G and U. In eukaryotes, modifications of RNA nucleotides are in general directed by small nucleolar RNAs (snoRNA; 60–300 nt), found in the nucleolus and cajal bodies. snoRNAs associate with enzymes and guide them to a spot on an RNA by basepairing to that RNA. These enzymes then perform the nucleotide modification. rRNAs and tRNAs are extensively modified, but snRNAs and mRNAs can also be the target of base modification. RNA can also be methylated.
=== Combos === Combos offered by Raising Cane's feature their chicken fingers and signature dipping sauce. Depending on the combo, they will also come with other sides such as crinkle-cut fries, coleslaw, and Texas toast.
Sources: en.wikipedia.org
Norris was born and brought up in the Milton area of Glasgow, Scotland. He originally worked as a travel agent after leaving college, but after a few years in this role decided to retrain as a nurse. Friends described him as someone who loved being centre stage, and said he enjoyed amateur dramatics. His academic record was average, but he became known for being quick to anger and his aggressive confrontations with tutors and, later, employers. His behaviour towards university lecturers at the University of Dundee was described as "unacceptable". He constantly argued with his tutor, later saying that she "and I didn't exactly see eye to eye. I had a personality clash, basically 'cos I had one and she never, and she was my personal tutor." Shortly before he qualified, this tutor was known to have taught Norris about Jessie McTavish, a nurse convicted of murdering a patient with insulin at Ruchill Hospital in Glasgow, less than a mile from where Norris grew up. McTavish's conviction was overturned on appeal. Norris was then tasked with "reviewing" her conduct by the tutor. Learning about McTavish would later be regarded as a likely inspiration for Norris, and he would have believed at this point that insulin would be the "perfect" weapon for murder as it leaves the blood very quickly. Norris began working at Leeds General Infirmary after qualifying in June 2001, but quickly fell out with experienced authority figures, finding it difficult to be told 'no' or what to do.
The basic principles of the biosynthesis of lactobacillic acid were already clarified in 1961. Lactobacillic acid, as well as other naturally occurring cyclopropane fatty acids (also abbreviated as CFA or CPFA) are formed from the corresponding unsaturated fatty acids, which have one carbon atom less, and have a cis configuration on the cyclopropane ring. The precursor of lactobacillic acid (cis-11,12-methylenoctadecanoic acid) is thus cis-vaccenic acid (cis-11-octadecenoic acid). This was demonstrated by carbon isotope14C labeled precursors. With the help of the enzymes cyclopropane fatty acid synthase, a methylene group is added to the double bond of cis-vaccenic acid. The methylene group originates from S-adenosylmethionine. The unsaturated fatty acid is not free, but is bound as an ester within phospholipids. The reaction mechanism proceeds via the formation of a carbocation. The enzyme catalyzes the reaction only with unsaturated fatty acids whose double bond has a cis configuration; the corresponding trans isomers are not converted. When the bacteria are cultivated in a batch culture, the formation of CFA occurs suddenly at a certain point in time rather than steadily increasing in concentration. At the same time, a decrease in the concentration of the unsaturated fatty acid (as a precursor) is observed. The formation of cyclopropane fatty acid occurs at the end of the exponential phase of growth or in the early stationary growth phase.
Kahala Brands is a wholly owned subsidiary of Canada-based MTY Food Group Inc. of Montreal, Quebec. Based in Scottsdale, Arizona, Kahala is one of North America's largest holding company of franchise fast food restaurant companies. In May 2016, the publicly traded Canadian MTY Food Group announced a friendly takeover deal with the Kahala Brands. MTY agreed to pay about US$300 million to acquire Kahala. The two companies generated nearly $2 billion in revenues in the previous year. Jeff Smit was chosen to lead the US operations of MTY.
Sources: en.wikipedia.org
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.
Most approved incretin therapies target one or two receptors, while retatrutide engages three. The addition of glucagon receptor activity is intended to raise energy expenditure. This broader mechanism is the subject of ongoing research rather than established practice.
No regulatory agency has approved retatrutide for any indication as of available public information. Development remains in later-stage trials. Availability claims found online should be treated as unverified.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.